Cn /En

News Center

——

Company news

Industry news

Introduction to the SCID Mouse NK Efficacy Model of InnoModels Biotechnology

Author:

InnoModels

Release time:

2024-08-27

Introduction
With the rapid development of biomedicine, especially the continuous progress in the field of immunotherapy, it is especially important to find efficient and reliable experimental models to verify drug efficacy. InnoModels Biotechnology (Beijing) Co., Ltd. has made remarkable breakthroughs in the field of immunotherapy, especially in natural killer (NK) cell immunotherapy. The company has successfully developed an NK efficacy model based on SCID (Severe Combined Immunodeficiency) mice, which provides strong support for the development of NK cell-related drugs.
Overview of the SCID mouse model
The SCID mouse is a mouse model with an autosomal recessive purist Prkdcscid mutant that causes mice to exhibit severe combined immunodeficiency.SCID mice lack mature T and B lymphocytes but retain some functions of macrophages and NK cells. This model is uniquely advantageous in the efficacy assessment of NK cell-associated drugs because NK cells can function independently in the absence of interference from other immune cells.
Advantages of the InnoModels SCID Mouse NK Efficacy Model
1. High homology
Mouse NK cells are highly homologous to human NK cells in terms of their development, functional properties and acquisition of memory-like features. Therefore, the SCID mouse model has high accuracy in simulating human NK cell responses, providing a solid foundation for preclinical evaluation of NK cell immunotherapy drugs.
2. Efficient NK cell reconstitution
By optimizing the experimental conditions, InnoModels Biotechnology has successfully achieved efficient NK cell reconstitution in SCID mice. This not only improves the sensitivity of drug evaluation, but also makes the pharmacodynamic response closer to the actual clinical situation.
3. Stable pharmacodynamic response
The SCID mouse model shows high stability during drug evaluation and can accurately reflect the effects of different drugs on NK cells. In addition, the model can also conveniently predict the efficacy of different donors, the degree of matching with tumor cells, and their ability to trigger graft-versus-host disease (GVHD), thus improving the reliability and reproducibility of the experimental results.
Model Application and Experimental Procedure
Applications
The SCID mouse NK efficacy model is widely used in the preclinical evaluation of NK cell-related drugs, including immune checkpoint inhibitors, NK cell activators, and ADCC drugs targeting tumor-specific targets. In addition, the model can also be used to validate the efficacy of innovative therapies such as CAR-NK cell therapy.

Experimental Procedure
1. **Model preparation**: select healthy SCID mice as experimental subjects, and ensure that the mice do not have other immunodeficiencies or diseases.
2. **NK Cell Reconstruction**: Through specific experimental methods, NK cells are reconstructed in the mice to reach a certain number and activity level.
3. **Drug administration**: mice are injected with the NK cell-related drug to be evaluated according to the experimental design.
4. **Drug Efficacy Assessment**: At different time points after drug administration, blood and tissue samples of mice are collected to detect changes in the number, activity and function of NK cells, and to assess the growth of tumor cells at the same time.
5. **DATA ANALYSIS**: Based on the experimental results, analyze the effect of the drug on NK cells and its anti-tumor effect, and provide data support for further development of the drug.
Conclusion
The SCID mouse NK efficacy model successfully developed by InnoModels Biotechnology provides a reliable platform for preclinical evaluation of NK cell immunotherapy drugs. The model not only has the advantages of high homology, efficient NK cell reconstitution and stable pharmacodynamic response, but also is widely used in the development of many NK cell-related drugs. With the deepening of the research, it is believed that the model will play an even more important role in the future and promote the further development of the immunotherapy field.

Immunogenicity Detection Platform of InnoModels Biotechnology

Analysis of the technical features of the iHuPBMC-B platform of InnoModels Biotechnology

Immunogenicity Detection Platform of InnoModels Biotechnology

Analysis of the technical features of the iHuPBMC-B platform of InnoModels Biotechnology

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License